ACS Medicinal Chemistry Letters · 2022 · 16 citations · 8 references
Life SciencesMedicinal ChemistryPharmacologyDrug DiscoveryStructural BiologyStructure-activity RelationshipsEnzyme FunctionEnzyme InhibitionLigand BindingProtein StructureBivalent BindingChemical Space DesignCysteine-targeted InhibitorsLipid AcylationMechanism-based InhibitorsPost-translational Lipid ModificationStructure - Activity Relationship MappingThioester Chemistry
Protein S-acylation is a dynamic and reversible lipid post-translational modification that can affect the activity, stability, localization, and interactions of target proteins. Lipid modification occurs on cysteine residues via a thioester bond and in humans is mediated by 23 Asp-His-His-Cys domain-containing protein acyltransferases (DHHC-PATs). The DHHC-PATs have well-known roles in physiology and disease, but much remains to be discovered about their biological function and therapeutic potential. We recently developed cyanomyracrylamide (CMA), an acrylamide-based DHHC inhibitor with key improvements over existing inhibitors. Here we conduct a structure–activity relationship (SAR) study of CMA and its acrylamide derivatives against zDHHC20, the most structurally characterized member of the human DHHC family, and validate the results against the homologous zDHHC2. This SAR maps out the limitations and potential of the acrylamide scaffold, underscoring the need for a bivalent inhibitor and identifying along the way three molecules with activity on par with CMA but with an improved logP.
8
Fatty acyl recognition and transfer by an integral membrane <i>S</i> -acyltransferase
Mitra S. Rana, Pramod Kumar, Chul-Jin Lee et al. · Science · 2018 · 260 citations · Full text
Development of an Acrylamide-Based Inhibitor of Protein <i>S</i> -Acylation
Saara‐Anne Azizi, Tong Lan, Clémence Delalande et al. · ACS Chemical Biology · 2021 · 61 citations · Full text